OKYO OKYO Pharma Inc: Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Logo korporat perusahaan OKYO Pharma Limited (OKYO)

International patent protection is critical for OKYO Pharma Limited (OKYO) due to geopolitical risks associated with drug registration. The brand's success relies on the launch of anti-inflammatory drops for patients with "dry eye," and analyst expectations for N+1 profit dynamics on GURU.Markets indicate that the metric level is -200.50. Currently, OKYO Pharma Limited (OKYO) is systematically spending investor capital on clinical trials in the complete absence of revenue.

OKYO Pharma Limited (OKYO): Prakiraan wutah bathi kanggo taun ngarep saka 27.06.2023 nganti 17.11.2026

Rincian metrik lan analitis perusahaan OKYO Pharma Limited (OKYO)

- rega lan prakiraan konsensus rega:
- data kapitalisasi saham perusahaan:
Pambiji fundamental perusahaan:OKYO, okyopharma.com
Barang utama OKYO Pharma Inc

This indicator measures the consensus earnings forecast for the upcoming period, isolating the long-term fundamental trend from market noise. The current value of -200.50 in the next year's EPS projections for OKYO Pharma Limited (OKYO) reflects market expectations regarding the commercialization of the OK-101 drug for the therapy of neuropathic pain. The positive trajectory of this metric signals capital's readiness to invest in a unique non-hormonal treatment mechanism for ophthalmological pathologies.

Karo sapa OKYO Pharma Limited saingan

ALC (Alcon Corp) - Prakiraan wutah bathi kanggo taun ngarep|Bausch + Lomb Corporation (BLCO) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep GKOS|Prakiraan wutah bathi kanggo taun ngarep Apellis Pharmaceuticals, Inc. (APLS)|Prakiraan wutah bathi kanggo taun ngarep BLTE (Belite Bio)|OCUL - Prakiraan wutah bathi saben saham kanggo taun ngarep|HROW - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Dinamika bathi saben saham sing diarepake ing taun ngarep VRDN (Viridian Therapeutics)|LENZ (LENZ Therapeutics, Inc.) - Prakiraan wutah bathi saben saham kanggo taun ngarep|Oculis Holding AG - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep eyepointpharma.com|Prakiraan wutah bathi kanggo taun ngarep Kodiak Sciences Inc.|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Aldeyra Therapeutics Inc. (ALDX)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep KALA (KALA BIO)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep opusgtx.com IRD|ADVM - Prakiraan wutah bathi saben saham kanggo taun ngarep|OTLK: Prakiraan wutah bathi saben saham kanggo taun ngarep|CLSD (Clearside) - Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep|NBY: Prakiraan wutah bathi kanggo taun ngarep|Kiora Pharma (KPRX) - Prakiraan wutah bathi kanggo taun ngarep|ALIM (alimerasciences.com) - Prakiraan wutah bathi kanggo taun ngarep|eyenovia.com (EYEN) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep GHSI|OCUP (Ocuphire) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep OPT (Opthea Ltd)